Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Baijin Life Science HoldingsMNNGF 26 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates MNNGF with a GF Score™ of 26/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 909 Retail - Cyclical companies, Baijin Life Science Holdings ranks worse than 110010.89% on this metric.
During the past 12 months, Baijin Life Science Holdings's average EBITDA Per Share Growth Rate was -500.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Baijin Life Science Holdings was 62.10% per year. The lowest was -121.10% per year. And the median was 36.30% per year.
Baijin Life Science Holdings (OTCPK:MNNGF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Baijin Life Science Holdings 3-Year EBITDA Growth Rate Related Terms
MNNGF vs TPR: 3-Year EBITDA Growth Rate Comparison
For the Luxury Goods subindustry, Baijin Life Science Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baijin Life Science Holdings 3-Year EBITDA Growth Rate vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Baijin Life Science Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Baijin Life Science Holdings's 3-Year EBITDA Growth Rate falls into.
Baijin Life Science Holdings 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Baijin Life Science Holdings (MNNGF) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Baijin Life Science Holdings and its competitors. According to the industry distribution chart, Baijin Life Science Holdings ranks #999999 out of 909 companies in the Retail - Cyclical industry.
Is Baijin Life Science Holdings' 3-Year EBITDA Growth Rate too high?
Baijin Life Science Holdings' current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Baijin Life Science Holdings ranks #999999 out of 909 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Baijin Life Science Holdings has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Baijin Life Science Holdings' 3-Year EBITDA Growth Rate compare to TPR?
According to the Retail - Cyclical industry distribution chart, Baijin Life Science Holdings ranks #999999 out of 909 companies for 3-Year EBITDA Growth Rate. This places Baijin Life Science Holdings in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 5.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Retail - Cyclical company?
The median 3-Year EBITDA Growth Rate among Retail - Cyclical companies is 5.10, based on 909 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Baijin Life Science Holdings and its competitors. For the Retail - Cyclical industry, the median 3-Year EBITDA Growth Rate is 5.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baijin Life Science Holdings's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baijin Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, Baijin Life Science Holdings (MNNGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.10 — trading 100% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Baijin Life Science Holdings' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Baijin Life Science Holdings (MNNGF), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baijin Life Science Holdings (MNNGF) Overvalued in 2026?
Based on GuruFocus' analysis, Baijin Life Science Holdings stock appears to be overvalued.
The current stock price of $0.10 is trading 100% above its estimated GF Value™ of $0.05.
GuruFocus considers Baijin Life Science Holdings to be Significantly Overvalued.
Key valuation signals for MNNGF:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: $0.05 vs. price of $0.10 (100% above fair value)
No single metric tells the full story. See the MNNGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company has three business segment: jewelry business segment; strategic investment segment; and skincare business segment. The majority of revenue is coming from jewelry business segment.
26GF Score
Get the complete analysis for MNNGF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNNGF has been successfully added to your 
